Athenagen Advances Angiogenesis Drug to Clinical Testing
Athenagen Advances Angiogenesis Drug to Clinical Testing: "and our Phase II compound, GTS-21, targeting Alzheimer's disease and schizophrenia."
Previous
- Renewed Hopes for Beta-Amyloid Vaccine to Treat Alzheimer's
- Renewed Hopes for Beta-Amyloid Vaccine to Treat Alzheimer's
- Chinese Moss Extract Tested as Alzheimer's Drug - Forbes.com
- Axonyx and TorreyPines Therapeutics Announce Merger Agreement; Transaction Creates Robust Portfolio in the CNS Disease Area
- Pharma response to Alzheimer's drug ruling
- FoldRx Pharmaceuticals lands $43M in second round
- Tramiprosate (Alzhemed™) preclinical results
- Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 270482
- Allon Begins Enrolment for AL-208 Phase II Clinical Trial
- Scientific Paper Confirms Mechanism of Allon's Drugs
Resources
CDC: Morbidity and Mortality Weekly
Favorite podcasts
0 Comments:
Post a Comment
<< Home